

Application No. 10/536,533
Paper Dated: August 24, 2009
In Reply to USPTO Correspondence of May 22, 2009
Attorney Docket No. 4544-051675

AMENDMENTS TO THE CLAIMS

OK
This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

to
Enter
Claims 1-22 (Cancelled)

Claim 23 (Currently Amended): A process for preparing an agglutination reagent for detecting typhoid comprising:

- (a) preparing a polyclonal-monospecific antibody specific to *Salmonella* typhi;
- (b) preparing a latex particle suspension; and
- (c) coating a latex particle with said polyclonal-monospecific antibody specific to *Salmonella* typhi;

wherein said polyclonal-monospecific antibody specific to *Salmonella* typhi is prepared according to a method comprising:

- (i) raising a hyper immune sera against a purified protein encoded by a Flagellin gene specific to *Salmonella* typhi, and
- (ii) separating said polyclonal-monospecific antibody ~~fraction~~ from said hyper immune sera;

wherein said latex particle suspension is prepared according to a method comprising:

- (i) mixing 1% carboxylated latex particles ~~of size~~ and a 40 mM 2-N morpholinoethane sulphonic acid (MES) buffer of pH 5.5 to 6.0 in a ratio of 1:1, washing with a 20 mM MES buffer of pH 5.5 thereby forming a washed latex particle, and
- (ii) adding a 1-ethyl-3 (3-dimethyl-amino propyl) carbodiimide hydrochloride (EDC) in a 20 mM MES buffer of pH 5.5 to said washed latex particle in a ratio of 1:1, washing with a 20 mM MES buffer (pH 5.5); and

Application No. 10/536,533
Paper Dated: August 24, 2009
In Reply to USPTO Correspondence of May 22, 2009
Attorney Docket No. 4544-051675

AMENDMENTS TO THE CLAIMS

OK
This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

to
Claims 1-22 (Cancelled)

Claim 23 (Currently Amended): A process for preparing an agglutination reagent for detecting typhoid comprising:

- enter
- (a) preparing a polyclonal-monospecific antibody specific to *Salmonella typhi*;
 - (b) preparing a latex particle suspension; and
 - (c) coating a latex particle with said polyclonal-monospecific antibody specific to *Salmonella typhi*;

wherein said polyclonal-monospecific antibody specific to *Salmonella typhi* is prepared according to a method comprising:

- 9/21
- (i) raising a hyper immune sera against a purified protein encoded by a Flagellin gene specific to *Salmonella typhi*, and
 - (ii) separating said polyclonal-monospecific antibody ~~fraction~~ from said hyper immune sera;

wherein said latex particle suspension is prepared according to a method comprising:

- (i) mixing 1% carboxylated latex particles ~~of size~~ and a 40 mM 2-N morpholinoethane sulphonic acid (MES) buffer of pH 5.5 to 6.0 in a ratio of 1:1, washing with a 20 mM MES buffer of pH 5.5 thereby forming a washed latex particle, and
- (ii) adding a 1-ethyl-3 (3-dimethyl-amino propyl) carbodiimide hydrochloride (EDC) in a 20 mM MES buffer of pH 5.5 to said washed latex particle in a ratio of 1:1, washing with a 20 mM MES buffer (pH 5.5); and